Mather Group’s Genmab GMAB Stock Holding History

Mather Group’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-36	Closed	-$751	–	1821
2024 Q4	$751	Sell	36 -44	-55%	-$967	﹤0.01%	1629
2024 Q3	$1.95K	Hold	80	–	–	﹤0.01%	1493
2024 Q2	$2.39K	Sell	80 -29	-27%	-$822	﹤0.01%	1838
2024 Q1	$3.47K	Buy	+109	New	+$3.2K	﹤0.01%	1427

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Mather Group's GMAB Position: Q1 2025 in Review

Mather Group sold out of Genmab (GMAB) in Q1 2025, closing a stake of 36 shares — an estimated $751 sold.

Mather Group first reported a position in GMAB in Q1 2024 and held it in 4 quarters. The position peaked at $3.47K in Q1 2024. 219 funds tracked by Wall St. Rank hold GMAB as of Q1 2025.

Mather Group reported no remaining Genmab position as of Q1 2025 after selling out during the quarter.
Mather Group sold 36 Genmab shares in Q1 2025, an estimated $751.
Mather Group first reported a position in Genmab in Q1 2024 and held it in 4 quarters.
Mather Group's Genmab position peaked at $3.47K in Q1 2024.
219 funds tracked by Wall St. Rank held Genmab as of Q1 2025.

Based on Mather Group's 13F filing for Q1 2025, filed 25 Apr 2025.